May 14, 2026 08:03AM Cingulate reports Q1 2026 results, raises $14.9M in cash

Apr 6, 2026 04:34PM Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25

Mar 23, 2026 09:11AM Cingulate (CING) PT Lowered to $14 at Roth/MKM

Jan 15, 2026 04:08PM Cingulate increases ATM offering capacity by $8.4 million

Jan 12, 2026 05:11PM Cingulate Inc (CING) files $200M mixed shelf

Nov 18, 2025 04:27PM Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25

Oct 14, 2025 08:04AM FDA accepts Cingulate's drug application for ADHD treatment CTx-1301

Sep 17, 2025 08:45AM Cingulate secures exclusive US manufacturing deal for ADHD treatment

Aug 22, 2025 06:21AM Cingulate (CING) PT Raised to $62 at Ascendiant Capital

Aug 21, 2025 04:35PM Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 2Q25

Aug 15, 2025 09:02AM Cingulate places CEO on administrative leave, names interim leadership

Aug 6, 2025 08:45AM Cingulate submits FDA application for ADHD drug CTx-1301

Jul 29, 2025 08:01AM Cingulate receives $4.3 million FDA fee waiver for ADHD drug application

Jul 25, 2025 04:30PM Cingulate Inc (CING) Files for 2.5M Share Offering by Selling Stockholders

Jul 9, 2025 08:03AM Cingulate names Nilay Patel as chief legal officer ahead of FDA filing

Jun 18, 2025 08:00AM Stonegate Capital Partners Initiates Coverage on Cingulate Inc. (CING)

May 20, 2025 08:03AM Cingulate Inc (CING): Efficacy Results Announced from Cingulate’s Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD

May 14, 2025 08:04AM Cingulate Inc (CING): FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301

Apr 9, 2025 08:00AM Cingulate Inc (CING) Receives $3M Grant from Private Foundation

Apr 3, 2025 08:06AM Cingulate Inc (CING) Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-1301

Mar 4, 2025 09:02AM Cingulate Inc (CING) Reports Safety Results from Final Phase 3 Trials for CTx-1301

Jan 30, 2025 06:40AM Cingulate (CING) PT Raised to $20 at H.C. Wainwright

Jan 10, 2025 08:59AM Roth/MKM Starts Cingulate (CING) at Buy

Oct 7, 2024 09:06AM Cingulate Inc (CING) Files for 1.5M Share Offering by Selling Stockholders

Sep 27, 2024 06:30AM Cingulate Inc (CING) Files for 1.5M Share Offering by Selling Stockholders

Aug 19, 2024 06:54AM Cingulate Inc (CING) Files for 1M Share Offering by Selling Stockholders

Aug 16, 2024 11:33AM Cingulate Inc (CING) halted on volatility, up 182%

Aug 15, 2024 07:45AM Cingulate Inc (CING) Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD

Aug 13, 2024 10:23AM Cingulate Inc (CING) Misses Q2 EPS by 547c

Jun 28, 2024 09:16AM Cingulate Inc (CING) Receives $1.86M from Warrant Exercise

Jun 25, 2024 09:20AM Cingulate (CING) Achieves Key Manufacturing Milestone in the Development of CTx-1301